WATCHMAN FLX Shows Bleeding Advantage, Matches EfficacyThe CHAMPION-AF study results shared on Saturday highlighted the WATCHMAN FLX device’s efficacy compared to traditional blood thinners as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF), a common heart rhythm disorder.The CHAMPION-AF trial demonstrated that the WATCHMAN FLX device provided statistically superior protection from bleeding while showing similar efficacy to non-vit ...

CHAMPION-AF study of the WATCHMAN FLXâ"¢ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints Accessibility StatementSkip Navigation Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation Late-breaking findings presented at ACC.26 and simultaneously published in ...